Pre-Conference Workshop Day
Tuesday June 21, 2022
WORKSHOP A: Working With CDMO’s, Streamline Your Drug Development Program
As the market edges closer to the first commercially available approved microbiome-based therapeutic, working effectively and efficiently with CDMO’s is necessary. This workshop will be sure to help your drug development program successfully partner and work with your chosen CDMO, saving time, money and effort.
- Learn how to find the right end-to-end solution to fulfill your R&D and manufacturing requirements
- Listen to how the perfect approach enables you to forge relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations
- Discover how choosing the right CDMO can ensure you are successfully guided all the way from pre-formulation and formulation development, through to clinical trials and commercial production
Associate Director Strain Process Development
Senior Director Product Development
Associate Director Microbial Development Team
WORKSHOP B - PART 1: Microbiome-Driven Liquid Biopsy is Enabling Earlier Cancer Detection - How to Avoid a Therapeutic Void at the Early Stage of Oncology Treatment?
The diagnostic implications of microbiome markers in tissue and liquid biopsies are endless. As the only cancer diagnostic company using the microbiome to detect early-stage cancer, Micronoma has the cutting-edge advantage. Starting with lung cancer, which has the highest need for early detection in terms of incidence and mortality rates, we can make a big difference in the lives of the many patients affected each year.
- Using circulating Microbiome is enabling to tackle early cancer detection as never before
- Patients have a better survival rate at early stage, but mostly rely on surgical solutions
- Should we develop or adapt at new therapies as alternatives to cancer resection at Stage I or II of the disease
WORKSHOP B - PART 2: How Protecting & the Restoring Gut Microbiome Could Improve Survival Outcomes in Hemato-oncology?
Patients with liquid tumors (such as leukemia or lymphoma) may receive an allogeneic hematopoietic stem cells transplantation (allo-HCT) to replace their cancerous cells. This is a highly desirable treatment, as it can be curative of the cancer. In these patients, intensive chemotherapy and antibiotic treatments that are administered to prepare for the allo-HSCT procedure result in a severely damaged gut microbiome. Importantly, higher gut microbiome diversity at the time of allo-HSCT has been correlated to higher survival and lower risks of complications, including incidence of graft-vs-host-disease and multi-resistant infections. MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
- Microbiome restoration approach in onco-hematology
- Global overview of MaaT033, MaaT Pharma’s second product is an oral, full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness Microbiome Ecosystem Therapy
- Presentation of the results for the dose-ranging Phase 1b CIMON trial with MaaT033 in patients with acute myeloid Leukemia
WORKSHOP B - PART 3: What Can We Learn From FMT Murine Models?
- Multiple variables affect FMT murine models, including sex and cage effect, and controlling these factors may lead to more consistent results
- Post human to mouse FMT, a subset of human bacteria can establish in mice. The abundance after FMT correlated with abundance in the inocula with more variability in low abundance OTUs
- Three Clostridia species correlated with tumor response in R-FMT mice treated with anti-PD-L1 antibody, along with Multiple T and NK cell immune pathways
Sandrine Miller Montgomery
President and CEO
Fyza Shaikhm MD PhD
Assistant Professor, Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine
Speaker to be announced
WORKSHOP C - PART 1: Gut-Brain Axis: Understanding How we can Better Direct Product Development That Would Unlock This Unique Space in the Field
Causal Effect Relationship Between Stress Induced Depression in Alzheimer’s Disease (AD) Progression Through Single Bacteria Modulating Regulatory T cell (Treg) and Th17 cells (Th17) Immunity
- Role of T cell regulation of IL-15 and IL-17 in the attenuation of Segmented Filamentous Bacteria (SFB) mediated cognitive deterioration through mitigation of mechanism associated to anxiety and depression
- Investigation of the role of IL-17a production in the gut lamina propria in the regulation of Th17 responses in the meningeal compartment of SFB mice
- Translational studies to alleviates anxiety and depression in SFB positive mice through modulation of adaptive immunity, implications for novel AD therapies
WORKSHOP C - PART 2
Recent studies have demonstrated the value of further understanding of the gut brain axis. This axis is continuously gaining more attraction due to its proposed link to psychiatric, neurodevelopmental, age-related, and neurodegenerative disorders. Join this workshop to discover the recent developments in the understanding of the communication between the microbiota and the brain. Be part of this more detailed discussion to uncover cover where this field is heading and how understanding the gut-brain axis can transform your microbiome research.
- Discover the developments surrounding the CNS brain disorder, Parkinson’s Disease and Alzheimer’s Disease
- Discover the exciting emphasis on cognitive health that has the potential to transform the way we think about our mental health
- Understanding how we can better direct product development that would unlock this unique space in the field
Saunders Family Chair and Professor of Neurology
Icahn School of Medicine at Mount Sinai